Oct 28, 2025 7:05 AM Eastern Daylight Time NeoGenomics Reports Third Quarter 2025 Results Share Third quarter total revenue increased 12% YoY to $188 millionClinical revenue grew 18%, or 15% excluding the Pathline acquisitionNGS revenue increased 24% YoY and now accounts for nearly one- third of clinical revenueRe-affirming full-year guidance for revenue, net loss and adjusted EBITDA FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the "Company†), a leading provider of oncology diagnost ...